Ractigen Therapeutics
Edit

Ractigen Therapeutics

http://www.ractigen.com/
Last activity: 15.09.2026
Active
Categories: BioTechNeurologyOncologyRNATherapeutics
Ractigen Therapeutics is an early-stage biotech company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.
Followers
271
Mentions
30
Location: China
Employees: 51-200
Total raised: $61M
Founded date: 2017
Twitter
Facebook
LinkedIn
Email

Funding Rounds 2

DateSeriesAmountInvestors
29.07.2026-$31MChina Ever...
28.01.2022Series A$30MSDIC Ventu...

Mentions in press and media 30

DateTitleDescription
15.09.2026Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle SocietyLate-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program committee determines to be of immediate importance to the field Presentation expected to provide the first clinical e...
31.07.2026Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative VitreoretinopathyRAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to ta...
30.07.2026P-1 AI Closes Series A FundingP-1 AI, Inc., a San Mateo, CA-based provider of an AI mechanical and electrical engineer solutions for industrial teams, raised an undisclosed amount in Series A financing. The round was led by New Enterprise Associates (NEA). The company i...
29.07.2026Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery PlatformsFunding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 2...
15.07.2026Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS— Peer-reviewed publication details RAG-17's robust translation from "bench to bedside," validating the proprietary SCAD™ delivery platform for CNS-targeted RNAi therapies — — First-in-Human trial met primary safety endpoints with...
06.06.2026Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity ControlBreakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEAN...
22.04.2026Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II tri...
19.03.2026Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder CancerNANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...
13.01.2026Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALSNANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic latera...
12.12.2025Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular DystrophyNANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) o...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In